GlassScriptPhysician profile
Robert T Spencer
NPI 1497787352
$19,975.28
in general payments reported to CMS, 2019-2025
37 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $5,971 · 2022: $26.26 · 2023: $707 · 2024: $1,014 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,946 · Education: $16.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.98 |
| Education | $16.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15,870.38 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $819.10 | 2019-2025 | Rinvoq |
| Ucb, INC. | $554.55 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $503.50 | 2019-2025 | |
| Genentech USA, INC. | $265.87 | 2019-2024 | Actemra |
| Glaxosmithkline, LLC. | $221.61 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $182.68 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $160.95 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $149.73 | 2023-2025 | Saphnelo |
| Lilly USA, LLC | $135.35 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.95 | 2019-2024 | Cyltezo |
| Sobi, INC | $104.43 | 2024-2025 | |
| Radius Health, INC. | $75.23 | 2019-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $71.64 | 2023-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $66.94 | 2019-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.